When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that depletes B cells, the immune cells that drive MS progression. Exactly how ocrelizumab does this, however, remains unclear. In a new study published in The Journal …
RNA sequencing reveals how ocrelizumab reshapes immune responses in multiple sclerosis
Share.
